non-dolutegravir antiretroviral drug exposure

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15